Phillips-Medisize, a manufacturer of pharmaceutical delivery systems, medical devices, and diagnostic products, announced on Monday that it will be closing its factory in Medford, Wisconsin, USA, which currently employs 170 people. The company, headquartered in Hudson, Wisconsin, stated that it will be phasing out the Medford facility by the end of 2023.
Spokesperson Sally Hoffman stated that Phillips-Medisize operates in a constantly evolving market, which requires us to continually assess global conditions and capabilities to ensure long-term competitiveness.
In the past few months, companies across industries have implemented layoffs due to concerns about economic recession and macroeconomic fluctuations. In July, Phillips-Medisize laid off 99 employees and closed its Crois Meadows factory in Hudson, citing a significant reduction in production demand from a major client.
Representatives of Juul Labs, a manufacturer of e-cigarettes, confirmed this month that Juul has reduced its order demand. Phillips-Medisize produces some of the electronic cigarette components for Juul, but the recently closed Medford factory did not manufacture components for Juul, and the closure is unrelated to the company. A spokesperson for Juul stated that there has been no change in recent production demands.
Phillips-Medisize, a company established in the 1960s, employs approximately 2,300 workers across multiple locations in Wisconsin, including Hudson, Eau Claire, New Richmond, Menomonie, and Phillips. In 2017, the electronic company Molex, headquartered in Illinois, acquired Phillips-Medisize. Molex is owned by Koch Industries, a corporate group based in Kansas.
A spokesperson for Phillips-Medisize, Hoffman, stated that the company has job openings in Wisconsin and other locations, and that the affected employees will have the option to apply for these positions as well as those at other Molex and Koch locations. The company will also provide severance packages and targeted employee assistance in the coming months.
Statement
This article is compiled from third-party information and is intended for industry professionals for the purpose of learning and exchanging ideas.
This article does not represent the views of 2FIRSTS and they cannot confirm the authenticity and accuracy of its contents. The translation of this article is solely for industry-related communication and research purposes.
Due to limitations in the level of translation, the translated article may not fully represent the original text. Please refer to the original text for accuracy.
2FIRSTS maintains complete alignment with the Chinese government on any domestic, Hong Kong, Macao, Taiwan, or foreign-related statement and position.
The copyright of compiled information belongs to the original media and author. If there is any infringement, please contact us to have it removed.
Disclaimer
This article is provided solely for professional research, industry discussion, and informational purposes. Any references to brands, companies, products, technologies, or policies are made for factual reporting and analytical purposes only, and do not constitute endorsement, recommendation, promotion, or advertising by 2Firsts.
Nicotine-containing products, including but not limited to cigarettes, e-cigarettes, heated tobacco products, and nicotine pouches, carry significant health risks. Readers are responsible for complying with all applicable laws and regulations in their respective jurisdictions, including age restrictions and access limitations.
The information contained in this article should not be regarded as investment, legal, medical, regulatory, or commercial advice. While 2Firsts strives to ensure the accuracy and reliability of its content, it does not assume liability for any direct or indirect loss arising from errors, omissions, inaccuracies, or reliance on the information contained herein.
This article is not intended for individuals below the legal age for accessing tobacco or nicotine-related information in their jurisdiction.
Copyright Notice
This article is either original content produced by 2Firsts or content reproduced, translated, summarized, or adapted from third-party sources with attribution where applicable. The intellectual property rights of the original content remain with 2Firsts or the respective original rights holders.
No individual or organization may copy, reproduce, distribute, republish, modify, translate, or otherwise use this content without prior authorization. Any unauthorized use may result in legal action.
For copyright-related inquiries, corrections, or removal requests, please contact: info@2firsts.com.
AI-Assisted Translation and Editing Notice
Portions of this article may have been translated, edited, or reviewed with the assistance of artificial intelligence tools to improve efficiency and readability. Due to the limitations of AI-assisted translation and editing, discrepancies, omissions, or inaccuracies may exist when compared with the original source.
Where applicable, readers are advised to refer to the original source for the most complete and accurate information. If you identify any errors or believe that any content infringes upon your rights, please contact us at info@2firsts.com, and we will review and address the matter promptly.
